ArticleScience advances2026
S1P receptor 1 signaling reduces arterial thrombosis via up-regulation of endothelial thrombomodulin expression.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingosine-1-phosphate (S1P) is a key mediator in the cardiovascular system with controversial effects on coagulation. We hypothesized that S1P reduces platelet adhesion and thrombus formation by up-regulating endothelial thrombomodulin (TM), an antithrombotic protein. S1P increased endothelial TM expression via S1P receptor 1 and phosphoinositide 3-kinase signaling. S1P reduced platelet adhesion on endothelial cells in flow-chamber experiments. In the absence of endothelial cells, S1P did not affect platelet activation. In mice, S1P enhanced endothelial TM expression and decreased in vivo arterial thrombus formation but did not change bleeding time. Conversely, sphingosine kinase 1-deficient mice with low S1P concentrations showed reduced endothelial TM expression and enhanced thrombus formation, reversible by TM treatment. In line with this, in an all-comer cohort of 74 patients with cardiovascular disease, higher S1P concentrations were associated with lower circulating thrombin concentrations. In conclusion, S1P inhibited thrombus formation in an endothelium- and TM-dependent manner. This might be a therapeutic target in prevention of thrombus formation without enhancing bleeding risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.